VIB and V-Bio Ventures have both participated in a series A round for Muna Therapeutics, the result of a merger of two recent spinouts.
Muna Therapeutics, a Denmark-based developer of treatments for neurodegenerative diseases, closed a $73m series A round today backed by VIB and its venture capital affiliate V-Bio Ventures.
Pharmaceutical firm Novo, Sofinnova Partners, Droia Ventures and LSP Dementia co-led the round, with additional participation from Sanofi Ventures, the strategic investment arm of pharmaceutical firm Sanofi, Polaris Partners and Polaris Innovation Fund.
Muna Therapeutics is focused on neurodegenerative diseases for which no cure is currently available and for which palliative care is scarce.
It has created a small molecule drug discovery engine that uses artificial intelligence-powered computational chemistry, cell-based screening and high-resolution target structural approaches.
The capital has been allocated to progressing candidates through to investigational new drug applications. Muna’s pipeline consists of assets aimed at repairing neuronal dysfunction, treating neuroinflammation and restoring neuroprotection and resilience to disease.
Muna is the result of a merger between two…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
